ALZCHEM GROUP AG (ACT.DE) Fundamental Analysis & Valuation

FRA:ACT • DE000A2YNT30

Current stock price

173.1 EUR
-2 (-1.14%)
Last:

This ACT.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. ACT.DE Profitability Analysis

1.1 Basic Checks

  • ACT had positive earnings in the past year.
  • ACT had a positive operating cash flow in the past year.
  • In the past 5 years ACT has always been profitable.
  • Of the past 5 years ACT 4 years had a positive operating cash flow.
ACT.DE Yearly Net Income VS EBIT VS OCF VS FCFACT.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

1.2 Ratios

  • ACT has a better Return On Assets (10.27%) than 92.86% of its industry peers.
  • ACT's Return On Equity of 24.76% is amongst the best of the industry. ACT outperforms 100.00% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 13.72%, ACT belongs to the top of the industry, outperforming 95.71% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for ACT is significantly above the industry average of 6.97%.
  • The 3 year average ROIC (13.60%) for ACT is below the current ROIC(13.72%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 10.27%
ROE 24.76%
ROIC 13.72%
ROA(3y)9.87%
ROA(5y)8.8%
ROE(3y)24.16%
ROE(5y)24.97%
ROIC(3y)13.6%
ROIC(5y)11.74%
ACT.DE Yearly ROA, ROE, ROICACT.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

1.3 Margins

  • The Profit Margin of ACT (11.29%) is better than 87.14% of its industry peers.
  • ACT's Profit Margin has improved in the last couple of years.
  • ACT has a Operating Margin of 16.87%. This is amongst the best in the industry. ACT outperforms 85.71% of its industry peers.
  • ACT's Operating Margin has improved in the last couple of years.
  • Looking at the Gross Margin, with a value of 67.97%, ACT belongs to the top of the industry, outperforming 97.14% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ACT has grown nicely.
Industry RankSector Rank
OM 16.87%
PM (TTM) 11.29%
GM 67.97%
OM growth 3Y35.88%
OM growth 5Y14.09%
PM growth 3Y26.76%
PM growth 5Y16.8%
GM growth 3Y11.38%
GM growth 5Y1.65%
ACT.DE Yearly Profit, Operating, Gross MarginsACT.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

9

2. ACT.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ACT is creating value.
  • Compared to 1 year ago, ACT has less shares outstanding
  • The number of shares outstanding for ACT has been reduced compared to 5 years ago.
  • ACT has a better debt/assets ratio than last year.
ACT.DE Yearly Shares OutstandingACT.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
ACT.DE Yearly Total Debt VS Total AssetsACT.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • ACT has an Altman-Z score of 5.02. This indicates that ACT is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of ACT (5.02) is better than 91.43% of its industry peers.
  • ACT has a debt to FCF ratio of 1.13. This is a very positive value and a sign of high solvency as it would only need 1.13 years to pay back of all of its debts.
  • The Debt to FCF ratio of ACT (1.13) is better than 91.43% of its industry peers.
  • ACT has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of ACT (0.14) is better than 74.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 1.13
Altman-Z 5.02
ROIC/WACC1.85
WACC7.41%
ACT.DE Yearly LT Debt VS Equity VS FCFACT.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M 200M 250M

2.3 Liquidity

  • ACT has a Current Ratio of 2.49. This indicates that ACT is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of ACT (2.49) is better than 78.57% of its industry peers.
  • ACT has a Quick Ratio of 1.52. This is a normal value and indicates that ACT is financially healthy and should not expect problems in meeting its short term obligations.
  • ACT's Quick ratio of 1.52 is fine compared to the rest of the industry. ACT outperforms 72.86% of its industry peers.
Industry RankSector Rank
Current Ratio 2.49
Quick Ratio 1.52
ACT.DE Yearly Current Assets VS Current LiabilitesACT.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

7

3. ACT.DE Growth Analysis

3.1 Past

  • ACT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.57%, which is quite good.
  • The Earnings Per Share has been growing by 26.48% on average over the past years. This is a very strong growth
  • The Revenue has been growing slightly by 1.42% in the past year.
  • Measured over the past years, ACT shows a quite strong growth in Revenue. The Revenue has been growing by 8.19% on average per year.
EPS 1Y (TTM)18.57%
EPS 3Y28.42%
EPS 5Y26.48%
EPS Q2Q%13.74%
Revenue 1Y (TTM)1.42%
Revenue growth 3Y1.21%
Revenue growth 5Y8.19%
Sales Q2Q%-1.26%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.17% on average over the next years. This is quite good.
  • ACT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.68% yearly.
EPS Next Y4.62%
EPS Next 2Y13.75%
EPS Next 3Y17.17%
EPS Next 5YN/A
Revenue Next Year4.79%
Revenue Next 2Y10.64%
Revenue Next 3Y11.58%
Revenue Next 5Y10.68%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ACT.DE Yearly Revenue VS EstimatesACT.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
ACT.DE Yearly EPS VS EstimatesACT.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2 4 6 8

2

4. ACT.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 27.48, which means the current valuation is very expensive for ACT.
  • Compared to the rest of the industry, the Price/Earnings ratio of ACT is on the same level as its industry peers.
  • The average S&P500 Price/Earnings ratio is at 27.42. ACT is around the same levels.
  • ACT is valuated quite expensively with a Price/Forward Earnings ratio of 26.91.
  • The rest of the industry has a similar Price/Forward Earnings ratio as ACT.
  • ACT is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.24, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 27.48
Fwd PE 26.91
ACT.DE Price Earnings VS Forward Price EarningsACT.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, ACT is valued a bit more expensive than the industry average as 61.43% of the companies are valued more cheaply.
  • ACT's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 44.93
EV/EBITDA 14.28
ACT.DE Per share dataACT.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of ACT may justify a higher PE ratio.
  • ACT's earnings are expected to grow with 17.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)5.94
PEG (5Y)1.04
EPS Next 2Y13.75%
EPS Next 3Y17.17%

4

5. ACT.DE Dividend Analysis

5.1 Amount

  • ACT has a Yearly Dividend Yield of 1.20%.
  • ACT's Dividend Yield is comparable with the industry average which is at 2.17.
  • Compared to the average S&P500 Dividend Yield of 1.81, ACT is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.2%

5.2 History

  • On average, the dividend of ACT grows each year by 19.13%, which is quite nice.
Dividend Growth(5Y)19.13%
Div Incr Years6
Div Non Decr Years6
ACT.DE Yearly Dividends per shareACT.DE Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • 28.66% of the earnings are spent on dividend by ACT. This is a low number and sustainable payout ratio.
  • The dividend of ACT is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP28.66%
EPS Next 2Y13.75%
EPS Next 3Y17.17%
ACT.DE Yearly Income VS Free CF VS DividendACT.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M
ACT.DE Dividend Payout.ACT.DE Dividend Payout, showing the Payout Ratio.ACT.DE Dividend Payout.PayoutRetained Earnings

ACT.DE Fundamentals: All Metrics, Ratios and Statistics

ALZCHEM GROUP AG

FRA:ACT (4/24/2026, 7:00:00 PM)

173.1

-2 (-1.14%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)02-27
Earnings (Next)04-30
Inst Owners38.03%
Inst Owner ChangeN/A
Ins Owners28%
Ins Owner ChangeN/A
Market Cap1.76B
Revenue(TTM)562.12M
Net Income(TTM)63.46M
Analysts87.27
Price Target189.94 (9.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.2%
Yearly Dividend1.79
Dividend Growth(5Y)19.13%
DP28.66%
Div Incr Years6
Div Non Decr Years6
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.24%
PT rev (3m)5.24%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.86%
EPS NY rev (3m)-0.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-2.5%
Revenue NY rev (3m)-2.92%
Valuation
Industry RankSector Rank
PE 27.48
Fwd PE 26.91
P/S 3.13
P/FCF 44.93
P/OCF 12.86
P/B 6.88
P/tB 6.97
EV/EBITDA 14.28
EPS(TTM)6.3
EY3.64%
EPS(NY)6.43
Fwd EY3.72%
FCF(TTM)3.85
FCFY2.23%
OCF(TTM)13.46
OCFY7.78%
SpS55.22
BVpS25.18
TBVpS24.83
PEG (NY)5.94
PEG (5Y)1.04
Graham Number59.7392 (-65.49%)
Profitability
Industry RankSector Rank
ROA 10.27%
ROE 24.76%
ROCE 19.01%
ROIC 13.72%
ROICexc 16.03%
ROICexgc 16.16%
OM 16.87%
PM (TTM) 11.29%
GM 67.97%
FCFM 6.98%
ROA(3y)9.87%
ROA(5y)8.8%
ROE(3y)24.16%
ROE(5y)24.97%
ROIC(3y)13.6%
ROIC(5y)11.74%
ROICexc(3y)15.49%
ROICexc(5y)13.01%
ROICexgc(3y)15.65%
ROICexgc(5y)13.15%
ROCE(3y)18.84%
ROCE(5y)16.26%
ROICexgc growth 3Y18.84%
ROICexgc growth 5Y13.25%
ROICexc growth 3Y18.94%
ROICexc growth 5Y13.21%
OM growth 3Y35.88%
OM growth 5Y14.09%
PM growth 3Y26.76%
PM growth 5Y16.8%
GM growth 3Y11.38%
GM growth 5Y1.65%
F-Score7
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 1.13
Debt/EBITDA 0.3
Cap/Depr 366.97%
Cap/Sales 17.4%
Interest Coverage 54.63
Cash Conversion 112.78%
Profit Quality 61.81%
Current Ratio 2.49
Quick Ratio 1.52
Altman-Z 5.02
F-Score7
WACC7.41%
ROIC/WACC1.85
Cap/Depr(3y)203.37%
Cap/Depr(5y)168.11%
Cap/Sales(3y)9.66%
Cap/Sales(5y)8.22%
Profit Quality(3y)109.03%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.57%
EPS 3Y28.42%
EPS 5Y26.48%
EPS Q2Q%13.74%
EPS Next Y4.62%
EPS Next 2Y13.75%
EPS Next 3Y17.17%
EPS Next 5YN/A
Revenue 1Y (TTM)1.42%
Revenue growth 3Y1.21%
Revenue growth 5Y8.19%
Sales Q2Q%-1.26%
Revenue Next Year4.79%
Revenue Next 2Y10.64%
Revenue Next 3Y11.58%
Revenue Next 5Y10.68%
EBIT growth 1Y20.86%
EBIT growth 3Y37.52%
EBIT growth 5Y23.43%
EBIT Next Year45.19%
EBIT Next 3Y29.72%
EBIT Next 5Y22.18%
FCF growth 1Y-36.78%
FCF growth 3YN/A
FCF growth 5Y14.56%
OCF growth 1Y30.31%
OCF growth 3YN/A
OCF growth 5Y22.98%

ALZCHEM GROUP AG / ACT.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ALZCHEM GROUP AG?

ChartMill assigns a fundamental rating of 7 / 10 to ACT.DE.


What is the valuation status for ACT stock?

ChartMill assigns a valuation rating of 3 / 10 to ALZCHEM GROUP AG (ACT.DE). This can be considered as Overvalued.


What is the profitability of ACT stock?

ALZCHEM GROUP AG (ACT.DE) has a profitability rating of 9 / 10.


What is the valuation of ALZCHEM GROUP AG based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ALZCHEM GROUP AG (ACT.DE) is 27.48 and the Price/Book (PB) ratio is 6.88.


What is the earnings growth outlook for ALZCHEM GROUP AG?

The Earnings per Share (EPS) of ALZCHEM GROUP AG (ACT.DE) is expected to grow by 4.62% in the next year.